TR199900505T2 - - Google Patents

Info

Publication number
TR199900505T2
TR199900505T2 TR1999/00505T TR9900505T TR199900505T2 TR 199900505 T2 TR199900505 T2 TR 199900505T2 TR 1999/00505 T TR1999/00505 T TR 1999/00505T TR 9900505 T TR9900505 T TR 9900505T TR 199900505 T2 TR199900505 T2 TR 199900505T2
Authority
TR
Turkey
Prior art keywords
prophylaxis
formulation
treatment
controlled release
certain disorders
Prior art date
Application number
TR1999/00505T
Other languages
English (en)
Turkish (tr)
Inventor
Marie Milosovich Susan
Muldoon William
Albert Napper James
Rousseau Laurence
Sauer Joseph
Original Assignee
Smithkline Beecham P.L.C.
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham P.L.C., Smithkline Beecham Corporation filed Critical Smithkline Beecham P.L.C.
Publication of TR199900505T2 publication Critical patent/TR199900505T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
TR1999/00505T 1996-09-12 1997-09-08 TR199900505T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9619074.9A GB9619074D0 (en) 1996-09-12 1996-09-12 Composition

Publications (1)

Publication Number Publication Date
TR199900505T2 true TR199900505T2 (de) 1999-06-21

Family

ID=10799833

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/00505T TR199900505T2 (de) 1996-09-12 1997-09-08

Country Status (22)

Country Link
EP (1) EP0929301A2 (de)
JP (1) JP2001500150A (de)
KR (1) KR20000036039A (de)
CN (2) CN1235544A (de)
AR (1) AR008176A1 (de)
AU (1) AU724086B2 (de)
BR (1) BR9711734A (de)
CA (1) CA2265661A1 (de)
CO (1) CO5031291A1 (de)
CZ (1) CZ83299A3 (de)
GB (1) GB9619074D0 (de)
HU (1) HUP9904401A3 (de)
ID (1) ID19589A (de)
IL (1) IL128781A0 (de)
MA (1) MA24359A1 (de)
NO (1) NO991194D0 (de)
NZ (1) NZ334268A (de)
PE (1) PE2499A1 (de)
PL (1) PL332074A1 (de)
TR (1) TR199900505T2 (de)
WO (1) WO1998010762A2 (de)
ZA (1) ZA978133B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775597B1 (fr) * 1998-03-04 2001-04-20 Gattefosse Ets Sa Pellet administrable par voie orale apte a ameliorer la biodisponibilite de la substance active, procede de fabrication
CN1292696A (zh) 1998-03-11 2001-04-25 史密丝克莱恩比彻姆有限公司 组合物
DE19918325A1 (de) * 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
FR2796840B1 (fr) * 1999-07-26 2003-06-20 Ethypharm Lab Prod Ethiques Comprimes faiblement doses et procede de preparation
US6733781B2 (en) * 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
US8679533B2 (en) 2002-07-25 2014-03-25 Pharmacia Corporation Pramipexole once-daily dosage form
US20060252820A1 (en) * 2003-04-25 2006-11-09 Tetsuya Suzuki Composition for oral administration containing alkylene dioxybenzene derivative
DE602004002405T3 (de) * 2003-05-14 2013-06-20 Aptalis Pharma Limited Kontrollierte medikamentfreigabe zusammensetzung mit in vivo mechanikstresswiderstand
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
JP2005272347A (ja) * 2004-03-24 2005-10-06 Ohara Yakuhin Kogyo Kk 固形製剤の製造方法
WO2006015943A2 (en) 2004-08-13 2006-02-16 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
EP2345407A1 (de) 2004-08-13 2011-07-20 Boehringer Ingelheim International GmbH Tablettenformulierung mit verlängerter Freisetzung enthaltend Pramipexol oder ein pharmazeutisch annehmbares Salz, die Herstellungsmethode und die Verwendung der Tabletten
EP1970056A1 (de) * 2007-03-15 2008-09-17 Polichem S.A. Zeitspezifische Dosierformen mit verzögerter/pulsatiler Freisetzung
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0392803T3 (da) * 1989-04-13 2004-10-18 Beecham Group Plc Hidtil ukendte forbindelser
GB9409718D0 (en) * 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds
GB9421472D0 (en) * 1994-10-25 1994-12-07 Smithkline Beecham Plc Novel methods
AR004178A1 (es) * 1995-07-29 1998-11-04 Smithkline Beecham Plc Procedimiento para la formulacion de un farmaco, una composicion farmaceutica obtenible mediante este procedimiento y el uso de la misma.

Also Published As

Publication number Publication date
CA2265661A1 (en) 1998-03-19
NO991194L (no) 1999-03-11
CO5031291A1 (es) 2001-04-27
NO991194D0 (no) 1999-03-11
HUP9904401A3 (en) 2001-03-28
CN1235544A (zh) 1999-11-17
ID19589A (id) 1998-07-23
KR20000036039A (ko) 2000-06-26
WO1998010762A3 (en) 1998-06-04
PE2499A1 (es) 1999-03-24
WO1998010762A2 (en) 1998-03-19
CZ83299A3 (cs) 1999-08-11
ZA978133B (en) 1999-04-12
JP2001500150A (ja) 2001-01-09
BR9711734A (pt) 1999-08-24
CN1446535A (zh) 2003-10-08
GB9619074D0 (en) 1996-10-23
MA24359A1 (fr) 1998-07-01
HUP9904401A2 (hu) 2000-06-28
IL128781A0 (en) 2000-01-31
PL332074A1 (en) 1999-08-30
AU724086B2 (en) 2000-09-14
NZ334268A (en) 2000-10-27
EP0929301A2 (de) 1999-07-21
AR008176A1 (es) 1999-12-09
AU4128897A (en) 1998-04-02

Similar Documents

Publication Publication Date Title
NO964966L (no) Lactobacillusstammer av human opprinnelse, blandinger samt anvendelse derav
EE9700310A (et) N-propargüül-1-aminoindaani R-enantiomeeri, selle soolade ja kompositsioonide kasutamine
ZA981936B (en) Novel benzimidazole inhibitors of fructose 1,6-bisphosphatase.
TR199900505T2 (de)
CY2431B1 (en) Novel phenanthridines substituted in the 6 position.
PT755249E (pt) Utilizacao de inibidores da reaccao de maillard para o tratamento de doenca com base em amiloidose
AP2000001796A0 (en) The use of inhibitors of the renin-angiotensin system for the treatment of hypoxia or impaired metabolic function
DE69914357D1 (de) Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
IT1306560B1 (it) Dispositivo di regolazione e limitazione della miscela percarburatore.
CA2408541A1 (en) Treating eczema and/or psoriasis
NO991459D0 (no) Anvendelse av 1-hydroksy-2-pyridoner til behandling av hudinfeksjoner
BR0209883A (pt) Uso de inibidores da proteasoma para o tratamento de distúrbios do olho seco
ES2186807T3 (es) Inhibidores de trombina.
EP0938898A3 (de) Behandlung von Pruritus
ES2194104T3 (es) Uso de selegilina para el tratamiento de la perdida de audicion en mamiferos.
NO991734L (no) Pyrazolinoner for behandling av potensforstyrrelser
DK1133296T3 (da) Ny terapeutisk anvendelse af nicergolin
TR200002939T2 (tr) Paroksetin maleat
NO20005548L (no) Mykobakterieinhibitorer
BG101145A (en) USE OF (S)-ADENOSYL-L-METHIONINE (SAMe) AND ITS PHYSIOLOGICALLY COMPETIBLE SALTS FOR TREATING REPERFUSION DAMAGE TRIGGERED BY TEMPORARY FOCAL ISCHAEMIA
ITMI912466A1 (it) Uso di 1, 2 dipalmitoil-l-alfa-fosfatidil-n, n-dimetiletanolammina, in composizioni dermatologiche
DE59711240D1 (de) Verwendung von flupirtin zur therapie und prophylaxe von myokardinfarkt, schockniere und schocklunge
PT1052991E (pt) Utilizacao de loperamida para o tratamento de infeccoes microbianas
IL139303A0 (en) Treatment of arthritis and other similar conditions
AU2068395A (en) Use of antagonists of egf or tgf-alpha for the treatment and prophylaxis of acne